Orchid Pharma Intrinsic Value
Orchid Pharma (ORCHPHARMA) median intrinsic value is ₹395.44 from 9 valuation models (range ₹297–₹505), vs current price ₹988.60 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse Orchid Pharma ownership structure to track promoter, FII and institutional holdings.
ORCHPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Orchid Pharma intrinsic value across 9 models vs current price ₹988.60 — upside/downside and value range per method. For current market price and key ratios, visit ORCHPHARMA stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹412.72 | ₹330.18 - ₹495.26 | -58.3% | EPS: ₹18.76, Sector P/E: 22x |
| Book Value Method | asset | ₹505.10 | ₹454.59 - ₹555.61 | -48.9% | Book Value/Share: ₹252.55, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹385.88 | ₹347.29 - ₹424.47 | -61.0% | Revenue/Share: ₹192.94, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹395.44 | ₹355.90 - ₹434.98 | -60.0% | EBITDA: ₹140.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹395.44 | ₹316.35 - ₹474.53 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹296.58 | ₹266.92 - ₹326.24 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹296.58 | ₹266.92 - ₹326.24 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹494.30 | ₹444.87 - ₹543.73 | -50.0% | ROE: 7.5%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹326.50 | ₹293.85 - ₹359.15 | -67.0% | EPS: ₹18.76, BVPS: ₹252.55 |
ORCHPHARMA Intrinsic Value vs Market Price — All Valuation Models
Orchid Pharma fair value range ₹297–₹505 vs current market price ₹988.60 across 9 valuation models. Read Orchid Pharma dividend payments for the complete payout history and dividend yield track record.
ORCHPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Orchid Pharma median intrinsic value ₹395.44, current price ₹988.60 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of ORCHPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Orchid Pharma (ORCHPHARMA) is ₹395.44 (median value). With the current market price of ₹988.60, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹296.58 to ₹505.10, indicating ₹296.58 - ₹505.10.
Is ORCHPHARMA undervalued or overvalued?
Based on our multi-method analysis, Orchid Pharma (ORCHPHARMA) appears to be trading above calculated value by approximately 60.0%.
ORCHPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Orchid Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.99 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 7.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.51x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ORCHPHARMA Cash Flow Quality — Operating & Free Cash Flow
Orchid Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹19 Cr | ₹6 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹126 Cr | ₹-30 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹18 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹93 Cr | ₹93 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹24 Cr | ₹24 Cr | Positive Free Cash Flow | 8/10 |